Report Card 2004: Biotech Hits and Misses
Looking over all the biotech stock stories I covered in 2004, I'm pleased to report that I was right more than wrong. My "win" column does veer in the bearish direction, which is not ideal (I'd prefer more of a balance), but then there were some spectacular biotech blowups in 2004 of which I had the good fortune of being on the right side. Here, then, is my self-graded report card for 2004.
My highlight reel has to start with Genta (GNTA) and its oh-so-controversial "antisense" cancer drug Genasense. I've talked in the past about how long it takes for biotech stories to reach their denouement, and after two years of skepticism in this column, it wasn't until May 2004 that Genta finally fell apart on the negative vote from a Food and Drug Administration advisory panel. Persistence and a lot of good research paid off on this one. Today, Genta is weakened but still alive, still trying to get Genasense approved. But I think the tough lessons learned in the spring have helped biotech investors become savvier and less gullible -- a good thing. Grade: A.
Cyberonics (CYBX) was a gut-wrenching test of the confidence in my research this year. After poring over clinical data and listening to as many experts as I could find, it became clear to me that the medical-device maker's VNS Therapy System would not -- should not -- be approved for the treatment of severe depression. The clinical data put together by Cyberonics were shoddy and unclear and simply didn't justify FDA approval -- and that's what I wrote repeatedly through the spring.
So I was more than a bit disheartened in June when an FDA advisory panel voted to recommend approval of the VNS device. Despite the setback, I stuck to my original thesis, believing the FDA would disregard the panel recommendation and reject Cyberonics' application for lack of convincing clinical data. I was proven right on Aug. 12, but all the noise around a possible takeover of Cyberonics kept the stock in play, and that knocked my grade down to an A-minus.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV